Dr. Frank Hensel
Principal / Authorized signatory
Dr Frank Hensel holds a PH.D. in biology and has a longstanding experience as Entrepreneur in a Start-Up developing human monoclonal antibodies for cancer treatment. Since being part of HTGF in 2015 Frank built a solid portfolio of start-ups with a focus on drug development companies. Out of this portfolio 3 companies already entered the clinical stage and one company, Amal therapeutics, was successfully exited to Boehringer Ingelheim with a deal volume of up to 425Mio. €
Contact
E-Mail:
f.hensel@htgf.de
f.hensel@htgf.de
Telefon:
+49 – (0)228 – 82300 – 142
+49 – (0)228 – 82300 – 142
